2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
Neurotrophic Factor GDF5 – an alternative to GDNF?
Neurotrophic factors are small protein that are naturally produced in the brain to help nurture and protect nerve cells (neurons). Cure Parkinson’s is a strong supporter of research exploring neurotrophic factors as a future therapeutic strategy for Parkinson’s.
The clinical trials pipeline for Parkinson’s: 2020/21
Despite the difficulties throughout 2020, a significant amount of clinical trial activity for Parkinson’s was conducted and a new report – involving the research team at Cure Parkinson’s – highlights the landscape of therapeutics being developed for Parkinson’s.
Encouraging trial results from Anavex
Recent positive results from biotech company Anavex Life Sciences have shown that when treated with their experimental drug, blarcamesine, individuals with Parkinson’s dementia had significant improvements in both motor and cognitive symptoms.
Improving Parkinson’s Trials: A Delphi Study
Under the visionary leadership of Dr Camille Carroll at the University of Plymouth, Cure Parkinson’s has been supporting an exploratory study at the University of Plymouth to understand the best way of improving clinical trials in order to speed up the development of new treatments…
Further funding announced for clinical studies and data investigation
After a year of disruption, clinical research has now restarted and lab-based research is getting back on track. Cure Parkinson’s is delighted to report that it is investing significant funds into research in the first quarter of 2021.